4.6 Article

USP15 targets ALK3/BMPR1A for deubiquitylation to enhance bone morphogenetic protein signalling

Journal

OPEN BIOLOGY
Volume 4, Issue 5, Pages -

Publisher

ROYAL SOC
DOI: 10.1098/rsob.140065

Keywords

bone morphogenetic protein; deubiquitylation; USP15; ubiquitin; ALK3; SMAD

Funding

  1. Medical Research Council [U117597140]
  2. AstraZeneca
  3. Boehringer-Ingelheim
  4. GlaxoSmithKline
  5. Merck-Serono
  6. Pfizer
  7. Johnson Johnson
  8. Medical Research Council [MC_U127092717, MC_UU_12016/3, MC_U117597140] Funding Source: researchfish
  9. MRC [MC_UU_12016/3, MC_U127092717, MC_U117597140] Funding Source: UKRI

Ask authors/readers for more resources

Protein kinase ALK3/BMPR1A mediates bone morphogenetic protein (BMP) signalling through phosphorylation and activation of SMADs 1/5/8. SMAD6, a transcriptional target of BMP, negatively regulates the BMP pathway by recruiting E3 ubiquitin ligases and targeting ALK3 for ubiquitin-mediated degradation. Here, we identify a deubiquitylating enzyme USP15 as an interactor of SMAD6 and ALK3. We show that USP15 enhances BMP-induced phosphorylation of SMAD1 by interacting with and deubiquitylating ALK3. RNAi-mediated depletion of USP15 increases ALK3 K48-linked polyubiquitylation, and reduces both BMP-induced SMAD1 phosphorylation and transcription of BMP target genes. We also show that loss of USP15 expression from mouse myoblast cells inhibits BMP-induced osteoblast differentiation. Furthermore, USP15 modulates BMP-induced phosphorylation of SMAD1 and transcription during Xenopus embryogenesis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available